Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Mattevi

Showing results (181-190 of 201) with videos related to

Pageof 21
Sort By:
European Journal of Medicinal Chemistry|March 14, 2015
Pure enantiomers of benzoylamino-tranylcypromine: LSD1 inhibition, gene modulation in human leukemia cells and effects on clonogenic potential of murine promyelocytic blastsSergio Valente, Veronica Rodriguez, Ciro Mercurio, et al.
ACS Infectious Diseases|May 6, 2017
A Phenotypic Based Target Screening Approach Delivers New Antitubercular CTP Synthetase InhibitorsMarta Esposito, Sára Szadocka, Giulia Degiacomi, et al.
Biorxiv : the Preprint Server for Biology|February 9, 2026
The glycine-arginine-rich motif of 53BP1 modulates RNA interactions necessary for its liquid-liquid phase separation during DNA Damage ResponseFederica Terraneo, Marta Ceccon, Oscar Sapkota, et al.
Journal of Medicinal Chemistry|December 12, 2013
Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activitiesDante Rotili, Stefano Tomassi, Mariarosaria Conte, et al.
Chemmedchem|February 1, 2020
Tranylcypromine-Based LSD1 Inhibitors: Structure-Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target ModulationRossella Fioravanti, Annalisa Romanelli, Nicola Mautone, et al.
ACS Chemical Neuroscience|August 12, 2025
Uncovering a Mutation-Independent Therapeutic Strategy against Inherited Retinal Diseases: Development of Class I HDAC/LSD1 Hybrid InhibitorsGabriele Carullo, Ilaria Piano, Giulia Salamone, et al.
Nature Chemical Biology|July 4, 2024
Uncoupling histone modification crosstalk by engineering lysine demethylase LSD1Kwangwoon Lee, Marco Barone, Amanda L Waterbury, et al.
Nature Chemical Biology|October 26, 2023
Targeting ROS production through inhibition of NADPH oxidasesJoana Reis, Christoph Gorgulla, Marta Massari, et al.
European Journal of Medicinal Chemistry|May 7, 2022
Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular modelsMartina Menna, Francesco Fiorentino, Biagina Marrocco, et al.
Journal of Medicinal Chemistry|February 11, 2017
Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 2: Structure-Based Drug Design and Structure-Activity RelationshipPaola Vianello, Luca Sartori, Federica Amigoni, et al.
Pageof 21

Showing results (181-190 of 201) with videos related to

Sort By:
Pageof 21
European Journal of Medicinal Chemistry|March 14, 2015
Pure enantiomers of benzoylamino-tranylcypromine: LSD1 inhibition, gene modulation in human leukemia cells and effects on clonogenic potential of murine promyelocytic blastsSergio Valente, Veronica Rodriguez, Ciro Mercurio, et al.
ACS Infectious Diseases|May 6, 2017
A Phenotypic Based Target Screening Approach Delivers New Antitubercular CTP Synthetase InhibitorsMarta Esposito, Sára Szadocka, Giulia Degiacomi, et al.
Biorxiv : the Preprint Server for Biology|February 9, 2026
The glycine-arginine-rich motif of 53BP1 modulates RNA interactions necessary for its liquid-liquid phase separation during DNA Damage ResponseFederica Terraneo, Marta Ceccon, Oscar Sapkota, et al.
Journal of Medicinal Chemistry|December 12, 2013
Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activitiesDante Rotili, Stefano Tomassi, Mariarosaria Conte, et al.
Chemmedchem|February 1, 2020
Tranylcypromine-Based LSD1 Inhibitors: Structure-Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target ModulationRossella Fioravanti, Annalisa Romanelli, Nicola Mautone, et al.
ACS Chemical Neuroscience|August 12, 2025
Uncovering a Mutation-Independent Therapeutic Strategy against Inherited Retinal Diseases: Development of Class I HDAC/LSD1 Hybrid InhibitorsGabriele Carullo, Ilaria Piano, Giulia Salamone, et al.
Nature Chemical Biology|July 4, 2024
Uncoupling histone modification crosstalk by engineering lysine demethylase LSD1Kwangwoon Lee, Marco Barone, Amanda L Waterbury, et al.
Nature Chemical Biology|October 26, 2023
Targeting ROS production through inhibition of NADPH oxidasesJoana Reis, Christoph Gorgulla, Marta Massari, et al.
European Journal of Medicinal Chemistry|May 7, 2022
Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular modelsMartina Menna, Francesco Fiorentino, Biagina Marrocco, et al.
Journal of Medicinal Chemistry|February 11, 2017
Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 2: Structure-Based Drug Design and Structure-Activity RelationshipPaola Vianello, Luca Sartori, Federica Amigoni, et al.
Pageof 21